Chimeron Bio receives NIH (NCI) Innovative Concept Award for mRNA cancer vaccine development

Philadelphia, PA – Chimeron Bio, a Philadelphia-headquartered biotech company, has received a 2024 National Institutes of Health’s Small Business Innovation Research Innovative Concept Award through the National Cancer Institute. The funding will support Chimeron Bio’s program developing a cancer vaccine against an inherited form of colorectal cancer.

Chimeron Bio will seek to develop a specialized vaccine using the company’s patented chimeric, multiplexed nanoparticle. The vaccine will utilize the company’s self-amplifying mRNA platform to train the immune system to target mutated, cancer-associated proteins in colorectal cancer cells.

“We’re thrilled to have the opportunity to implement our mRNA platform in the cancer vaccine space,” said Kevin Heyeck, CEO. “Cancer vaccine research is an imperative for medical science moving into the future, and we’re uniquely equipped to advance this field to address unmet needs for cancer patients.”

“We are grateful that the National Cancer Institute recognizes potential in Chimeron Bio’s unique approach to cancer vaccines with this support,” said Dr. Antonin de Fougerolles, Chimeron Board member.

This program builds on Chimeron’s cancer vaccine efforts within its cancer-focused platform that includes immune-oncology and in-vivo CAR cell therapy.

About Chimeron Bio

Chimeron Bio is an early-stage biotech company focused on breakthrough treatments of cancer. Chimeron’s patented Multiplex nanoparticle and self-amplifying mRNA technology enables delivery of multiple genes to transform the complex tumor micro-environment with a unique “All-in-One” treatment approach. Chimeron is developing a high-impact pipeline for the creation and delivery therapeutics with the potential for meaningful patient results. For more information, visit

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N91024C00011

“Being recognized as a finalist in MilliporeSigma’s Advance Biotech Grant is an honor,” said Kevin Heyeck, CEO of Chimeron Bio. “It recognizes the unique innovation of our platform and the support from the MilliporeSigma team will help us expedite our work and further scale solutions for next-generation RNA therapeutics.”

Since 2014, the Life Science business sector’s Advance Biotech Grant program has awarded technologies and consultation to nearly 40 biotechnology companies around the world, supporting their efforts to improve patient outcomes for various diseases such as cancer, brain tumors, osteoarthritis, and cardiovascular disorders. The company is set to award its next grant in the APAC region in July, further expanding its commitment to supporting emerging biotech companies worldwide.

About Chimeron Bio
Chimeron Bio is a biotechnology company dedicated to advancing genetic medicine through the development and delivery of next generation RNA therapeutics. Chimeron employs an innovative combination of its proprietary multiplex delivery vector and self-amplified RNA (saRNA) technology to create and deliver therapeutics with the potential for meaningful patient results. The company is developing a high-impact pipeline across a range of conditions including oncology, genetic disorders, and infectious diseases. For more information, visit

We're dedicated to advancing genetic medicine and transforming cancer treatment. Our groundbreaking delivery system enables unparalleled gene expression and therapeutic potency, making it ideal for developing pioneering in vivo CAR-T therapies.
Our innovative technology is also catalyzing advancements in immuno-oncology and cancer vaccines -- offering new hope in the battle against cancer.


900 900 Chimeron Bio | Redefining Cancer Therapeutics

To inquire about investment opportunities, email